← Back to the library

Tesamorelin

peptide

Egrifta · Egrifta WR

Growth-hormone-releasing hormone analog

Research status · FDA-approved (specific use)

FDA-approved for one specific use: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Any other use is off-label and not FDA-approved.

Tesamorelin (Egrifta) is the only FDA-approved GHRH analog, approved specifically for HIV-associated lipodystrophy. It is sometimes discussed more broadly for visceral fat; that broader use is off-label and a clinician-level decision.

How it works

GHRH analog that stimulates pituitary GH release, which can reduce visceral (deep abdominal) fat.

Commonly discussed use cases

  • HIV-associated lipodystrophy (approved)
  • Visceral fat (off-label, discussed)

Supposed / potential benefits

  • Reduced visceral adipose tissue in its approved population

Common side effects

  • Joint pain
  • Swelling / fluid retention
  • Injection-site reactions
  • Possible blood-sugar elevation

Warnings & contraindications

  • Contraindicated in pregnancy and with active malignancy
  • Can raise IGF-1 and affect glucose — requires monitoring
  • Off-label use is not FDA-approved and should be a clinician decision

Typical timing considerations

Approved regimen is a daily subcutaneous injection; follow the prescribing information.

Administration route

Subcutaneous injection

Storage

Refrigerate; reconstitute per label. Follow product instructions.

Questions to ask your clinician

  • Am I a candidate, and is this on- or off-label for me?
  • What glucose/IGF-1 monitoring do you want?
  • How long before we evaluate benefit?

Commonly tracked in Reta

Waist measurement (weekly)Weight trendJoint comfortInjection site rotationLab dates

Tracking fields organize user-entered, clinician-directed routines — Reta never recommends or computes doses.

Sources

Track this in Reta

Beta members get a ready-made tracker for Tesamorelin — schedule, dose log, injection-site rotation, reminders, and check-ins — for organizing a clinician-directed routine. Personal tracking is available to everyone during the Public Beta.

Reta is a tracking and education tool — not a medical provider. Nothing here is a diagnosis, treatment, prescription, or dosing recommendation. Peptides and medications should only be used under the direction of a licensed clinician. Talk to a qualified clinician before starting, stopping, combining, or changing anything. Many compounds below are not FDA-approved for human use; some are investigational or sold through unregulated channels where purity and dosing are not guaranteed.